Literature DB >> 16367939

CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses.

H Voigt1, D Schrama, A O Eggert, C S Vetter, K Müller-Blech, H M Reichardt, M H Andersen, J C Becker, F Lühder.   

Abstract

Costimulatory signals such as the ones elicited by CD28/B7 receptor ligation are essential for efficient T cell activation but their role in anti-tumour immune responses remains controversial. In the present study we compared the efficacy of DC vaccination-induced melanoma specific T cell responses to control the development of subcutaneous tumours and pulmonary metastases in CD28-deficient mice. Lack of CD28-mediated costimulatory signals accelerated tumour development in both model systems and also the load of pulmonary metastases was strongly increased by the end of the observation period. To scrutinize whether lack of CD28 signalling influences priming, homing or effector function of Trp-2(180-188)/K(b)-reactive T cells we investigated the characteristics of circulating and tumour infiltrating T cells. No difference in the frequency of Trp-2(180-188)/K(b)-reactive CD8+ T cells could be demonstrated among the cellular infiltrate of subcutaneous tumours after DC vaccination between both genotypes. However, the number of IFN-gamma-producing Trp-2-reactive cells was substantially lower in CD28-deficient mice and also their cytotoxicity was reduced. This suggests that CD28-mediated costimulatory signals are essential for differentiation of functional tumour-specific CD8+ T-effector cells despite having no impact on the homing of primed CD8+ T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16367939      PMCID: PMC1809563          DOI: 10.1111/j.1365-2249.2005.02972.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

Review 1.  CD28 and T cell co-stimulation.

Authors:  A D Holdorf; O Kanagawa; A S Shaw
Journal:  Rev Immunogenet       Date:  2000

Review 2.  Tuning tumor-specific T-cell activation: a matter of costimulation?

Authors:  Hinrich Abken; Andreas Hombach; Claudia Heuser; Kai Kronfeld; Barbara Seliger
Journal:  Trends Immunol       Date:  2002-05       Impact factor: 16.687

3.  Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture.

Authors:  Andreas O Eggert; Jürgen C Becker; Michael Ammon; Alexander D McLellan; German Renner; Angela Merkel; Eva-B Bröcker; Eckhart Kämpgen
Journal:  Eur J Immunol       Date:  2002-01       Impact factor: 5.532

Review 4.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

Authors:  C A Chambers; M S Kuhns; J G Egen; J P Allison
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Priming of memory but not effector CD8 T cells by a killed bacterial vaccine.

Authors:  G Lauvau; S Vijh; P Kong; T Horng; K Kerksiek; N Serbina; R A Tuma; E G Pamer
Journal:  Science       Date:  2001-11-23       Impact factor: 47.728

6.  CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer.

Authors:  I Hellstrom; J A Ledbetter; N Scholler; Y Yang; Z Ye; G Goodman; J Pullman; M Hayden-Ledbetter; K E Hellstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

7.  Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens.

Authors:  X F Bai; J Bender; J Liu; H Zhang; Y Wang; O Li; P Du; P Zheng; Y Liu
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

8.  Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses.

Authors:  M C Wolkers; G Stoetter; F A Vyth-Dreese; T N Schumacher
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

9.  4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.

Authors:  B A Guinn; E M Bertram; M A DeBenedette; N L Berinstein; T H Watts
Journal:  Cell Immunol       Date:  2001-05-25       Impact factor: 4.868

10.  Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression.

Authors:  Alexander D McLellan; Michaela Kapp; Andreas Eggert; Christian Linden; Ursula Bommhardt; Eva-B Bröcker; Ulrike Kämmerer; Eckhart Kämpgen
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

View more
  6 in total

Review 1.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

2.  miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.

Authors:  Krishan Jethwa; Jun Wei; Kayla McEnery; Amy B Heimberger
Journal:  Clin Investig (Lond)       Date:  2011-12

3.  New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer.

Authors:  Valeska B Guzman; Anatoly Yambartsev; Amador Goncalves-Primo; Ismael D C G Silva; Carmen R N Carvalho; Julisa C L Ribalta; Luiz Ricardo Goulart; Natalia Shulzhenko; Maria Gerbase-Delima; Andrey Morgun
Journal:  Hum Mol Genet       Date:  2008-03-12       Impact factor: 6.150

4.  Comparative Study of 5'- and 3'-Linked CpG-Antigen Conjugates for the Induction of Cellular Immune Responses.

Authors:  Katrin Kramer; Sarah L Young; Greg F Walker
Journal:  ACS Omega       Date:  2017-01-25

Review 5.  Varied functions of immune checkpoints during cancer metastasis.

Authors:  Ali Safarzadeh; Mohsen Alizadeh; Fatemeh Beyranvand; Reza Falavand Jozaaee; Khalil Hajiasgharzadeh; Amir Baghbanzadeh; Afshin Derakhshani; Antonella Argentiero; Behzad Baradaran; Nicola Silvestris
Journal:  Cancer Immunol Immunother       Date:  2020-09-09       Impact factor: 6.968

6.  The hedgehog receptor patched1 in T cells is dispensable for adaptive immunity in mice.

Authors:  Kai D Michel; Anja Uhmann; Ralf Dressel; Jens van den Brandt; Heidi Hahn; Holger M Reichardt
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.